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Abstract 
 
Background. South Africa is currently experiencing one of the most severe AIDS epidemics 
in the world. The major challenge lies in prompt identification and early initiation of treatment 
in those eligible for HAART. Clinical staging has previously been recommended for use in 
settings where CD4 + count testing is not available. We conducted secondary data analysis to 
determine whether clinical symptoms and signs are useful in predicting the need for HAART 
initiation (CD4 + count < 200 cells/µL) in South Africa. 
Methods.  Screening data from a randomized controlled trial in women who were HIV positive 
were analysed. All participants were interviewed using a structured questionnaire to elicit 
symptom history and then physical examination was done. Participants were staged using 
WHO criteria. Blood was drawn for CD4 + testing. The association between signs and 
symptoms and a CD4 + < 200 cells/µL was assessed using logistic regression.  
Results.  Among 589 HIV infected women aged between 18 and 58 years, 90% were assessed 
as WHO clinical stages I/II. The median CD4 + count was 403 cells/µL (IQR: 273-586). 
Among women who were WHO stage I/II, 13% had CD4 + count < 200 cells/µL and required 
HAART. The WHO clinical staging had a low sensitivity (4%) but high specificity for 
detecting those that require treatment. 
Conclusion: In a setting where asymptomatic patients are diagnosed with HIV, clinical 
assessment can not replace CD4 + count testing as a method of identifying those that need 
treatment. 
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                                 Chapter 1: Introduction and Literature Review 
1.0 Introduction and Background 
 
1.1 Historical rationale for WHO clinical staging 
 
The World Health Organization (WHO) AIDS surveillance case definition was first developed 
by WHO in October 1985 in Bangui, Central African Republic. It was then revised in 1994 
after a heavy criticism to incorporate the statement that HIV testing should be done. The AIDS 
case definition, and subsequent WHO clinical staging systems, have been proposed to be used 
in poor-resourced countries where laboratory facilities to test for CD4 + count are inaccessible 
(Grant, 2001). 
 
 The second revision of the WHO clinical staging system was in 2005.The WHO classification 
of HIV- associated clinical disease was revised in order to provide greater consistency between 
the adult and paediatric classification systems. Revisions were meant to form part of the 
baseline assessment (first visit) on entry into a care and treatment program and used to guide 
decisions on whether to start co-trimoxazole prophylaxis and when to start and switch ART in 
situations where CD4 + testing is not available (WHO,2006) 
 
The WHO clinical staging system for HIV/AIDS, as developed in 1990, emphasized the use of 
clinical parameters to guide clinical decision-making for the management of HIV/AIDS 
patients. The WHO clinical staging system is needed for use in resource-limited settings where 
there is a limited access to laboratory services. The system has been widely used in resource-
limited countries, particularly in the African Region (WHO, 2005). Several studies (Torpey, 
2009; Jaffar, 2008; Edathodu, 2007; Erkose, 2007; Kagaayi, 2007; McGrath, 2007) have 
evaluated the correlation between CD4 + count and WHO staging in Africa.   Three recent 
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studies (Torpey, 2009; Jaffar et al, 2008; McGrath, 2007) have indicated that the WHO clinical 
staging system is inadequate in correctly identifying individuals eligible for HAART initiation. 
The three studies suggested that CD4 + measurement is actually a much more accurate means 
to predict disease progression and hence the indication for HAART initiation as HAART 
became available. 
1.2 Global overview of HIV/AIDS 
An estimated 39 – 65 million people in the world were living with HIV/AIDS in 2007 
(UNAIDS, 2008). Approximately 96% of HIV/AIDS patients live in low and middle income 
countries, with sub-Saharan Africa being the region worst affected. Even though sub-Saharan 
Africa is home to only 10 % of the world’s population, 67% of all patients who are HIV 
positive reside here (UNAIDS, 2008). 
While most of the 40 million people living with HIV/AIDS at the end of 2006 were in low- and 
middle-income countries, 20% of those in need of treatment were receiving highly active 
antiretroviral therapy (HAART) (UNAIDS, 2006).  
Guidelines developed by the WHO for the use of HAART in low-income countries state that 
HIV– infected individuals should commence HAART if they have WHO stage IV disease, 
stage III disease and a CD4 + T lymphocyte cell counts of ≥ 350 cells/µL, or stages I or II 
disease with CD4 + cell count < 200 cells/µL (WHO, 2006). Recently WHO has recommended 
increasing this threshold for stages I and II individuals to 350 cells/µL (Brodt, 2009).  In many 
parts of sub-Saharan Africa, facilities for laboratory diagnosis and monitoring of CD4 + count 
are limited and inadequate to sustain the escalating of the HIV/AIDS epidemic (Jaffer, 2008).  
In resource-constrained settings, the cost of laboratory investigations is a key constraint that 
affects the initiation and monitoring of HAART (Torpey, 2009). 
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This study is undertaken to determine whether the use of clinical symptoms and signs alone is 
feasible and appropriate in asymptomatic individuals in a South African setting and hence in 
any high burden HIV setting especially in sub – Africa where laboratory diagnostic capacities 
are limited. 
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1.3 Problem Statement 
 
CD4+ T lymphocyte count decline is an important predictor of progression to AIDS. In the 
developed world, this parameter is used to identify patients who need prophylaxis for 
opportunistic infections and HAART. In countries with limited resources, despite the increased 
access to HAART, CD4+ count testing is often not available (Lynen, 2006). While CD4+ 
count is the best indicator for the need to commence treatment, CD4 + count determination is 
not feasible in settings with poor access to laboratory services or where demand for services is 
high. Barriers to initiation of appropriate antiretroviral treatment include lack of CD4+ count 
measurements in the laboratory and trained personnel to make accurate clinical staging of HIV 
(Costello, 2004;UNAIDS/WHO,2006). In these instances, it may be useful to identify those 
that need treatment at the time of their diagnosis. The performance of WHO staging is 
questionable (Torpey, 2009). It is also not clear how the WHO staging works in HIV + 
population in good health. There is increasing pressure to initiate treatment early (Brodt, 2009). 
Thus a need arises, therefore, to determine whether the use of clinical signs and symptoms 
alone is feasible and appropriate in a South African setting. 
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1.4 Literature review 
 
1.4.1 Prevalence of HIV in South Africa 
 
South Africa is one of the worst affected countries in the world by the HIV pandemic 
(Steinbrook, 2004). By the end of 2008, 5.2 million of the 48 million people were living with 
HIV in South Africa (HSRC, 2009), and almost 1,000 AIDS deaths occurring every day 
(UNAIDS/WHO, 2008). HIV prevalence among pregnant women has risen steadily from 10.4 
% in 1995 to 30.2 % (95% CI 29.1-31.2) in 2005. In the 2008 HSRC survey, amongst the 
general population, HIV prevalence was 10.6% (12.8% in females and 9.5% in males). 
Women are at a higher risk of HIV infection than men in South Africa. 
Evidence shows that women are at a higher risk of HIV infection than men. The South African 
National HIV prevalence, incidence, behaviour and communication survey  conducted in 2008 
showed that  females aged 15-19 years have an 2.7 times higher HIV prevalence than males 
(6.7% compared to 2.5%) and account for 83% of the recent HIV infections in this age group. 
In African adults aged 15-49 years the HIV prevalence was 16.9%.The figure for African 
women in the same age group is 24.4% (Shisana, 2009).Young women are particularly 
affected. A cross-sectional, nationally representative, household survey was done in South 
Africa among 11, 904 young people in the age group 15 - 24 year olds. The results showed that 
young women were significantly more likely to be infected with HIV in comparison with 
young men (15.5% versus 4.8%) (Pettifor, 2005).  
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Natural history of HIV infection 
In sub-Saharan Africa, the major route of HIV transmission is heterosexual in about 90% of 
cases. Initial infection with HIV is sub-clinical. This is followed by an asymptomatic phase 
lasting a median duration of 10 years (Jaffar, 2004). Early symptomatic infections include 
fever, unexplained weight loss, recurrent diarrhoea, fatigue and headache. Subsequent 
manifestations include cutaneous or dermatological conditions. Late symptomatic stage begins 
as the CD4 + count falls to lower than 200 cells/µL and the risk of developing AIDS-related 
opportunistic infections or malignancy increases (Mindel, 2001) (Fig.1.1). 
Figure 1.1 Schematic Natural History of HIV infection 
 
(Source: Mindel, 2001) 
There are few studies on the natural history of HIV infection among African populations, and 
little is known about the natural history of HIV infection in Africa. However, in a review, 
Jaffar (2004) showed that the time from infection to symptomatic (AIDS) phases was similar 
for sub Saharan African patients when compared to patients in developed countries prior to 
introduction of HAART. The authors noted that there was a more rapid progression from 
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symptomatic phase to death among sub-Saharan African cohorts than those of developed 
countries. The rapid progression was attributable to the background co-morbidities in among 
the patients from sub Saharan Africa notably tuberculosis, sexually transmitted infections, 
clinical malaria, and high malaria parasitaemia. The co-morbidities were coupled with a lack of 
treatment of these potentially curable infections due to poor clinical services (Jaffar, 2004). 
 
1.4.2 A need for HAART to treat opportunistic infections and prolong life 
 
HAART is currently recommended for at a CD4 + count < 200 cells per μL in South Africa 
(DOH, 2006). However, a recent computer simulation model of HIV disease has indicated that 
initiating HAART at a CD4 + count threshold of 350 cells per μL would remain cost-effective 
over the next 5 years before the results of clinical trials to determine the most plausible CD4 + 
count threshold for HAART initiation (Walensky, 2009). Treatment is started at this level in 
order to prevent opportunistic infections and death. With increased use of HAART the survival 
among even the advanced HIV disease patients has improved substantially (Mindel, 2001; 
Munderi, 2004; Castilla, 2005 and Louwagie, 2007). A study from Cape Town showed that 
delay in the initiation of treatment lead to the increase of mortality and morbidity (Lawn, 
2006). 
The best possible time to begin HAART has recently been established to be CD4 + count ≥ 350 
cells per μL where 18 cohort studies of patients with HIV were analysed (Brodt, 2009). 
However Wood et al, (2005) had described data from observational studies suggesting a longer 
term benefit when HAART is begun well before the CD 4 + count falls to 200 cells/µL or less. 
An  analysis of data from 10, 885 individuals who were AIDS free and ART-naive at onset of 
HAART found that the risk of  progression to AIDS was higher in those starting HAART at 
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CD4 + count 200 cells/µL or less (HR=3·30, 95% CI: 2·51–4·33)   compared to those with 
CD4 +  count 201–350 cells/µL, (HR=1·46, 95% CI: 0·96–2·21)  or 351–500 cells/µL after 
adjusting for lead-time bias and hidden events (Sterne , 2006). Further evidence of goals and  
importance of HAART is to prevent opportunistic infections, resistance to HAART and also to 
prevent the occurrence of non AIDS events (SMART trial, 2006). 
Two studies underscored other benefits of early initiation of HIV treatment. These benefits 
include potential effectiveness in reducing HIV secondary transmission (Castilla, 2005) and 
preservation of ability to use chemokine receptor CCR 5 entry inhibitors (Deeks, 2006).  
There is also strong evidence for the clinical benefit of HAART in adults with advanced 
HIV/AIDS as determined virologically, clinically and immunologically (WHO/HIV/2005). 
Munderi et al, (2004) conducted the Development of Anti-Retroviral Therapy in Africa trial on 
the CD4 + response to HAART in previously untreated adults with HIV infection in Africa. 
This trial was an open-label, randomized trial comparing 2 therapeutic approaches to be tested 
in resource-poor settings. Participants were 3,000 symptomatic ART-naive adults from 3 sites 
(2 in Uganda, 1 in Zimbabwe) who had CD4 + < 200 cells/µL who received 3-drug HAART, 
and were followed for 5 years. The trial showed an increase in CD4 + count (immunological 
response) whereby 49 % adults had an increase in CD4 + count by at least 100 cells/µL at 24 
weeks (median increase 98, IQR: 44-152).The trial concluded that achieving CD4 + count 
increases of > 100 cells after 24 weeks on HAART in Africa appears to occur regardless of 
pre-HAART factors including low baseline CD 4+ count.  
Munderi et al (2004) again showed the benefit of HAART among the participants in Entebbe 
cohort. The Entebbe cohort (EC) is an active, community-based clinical cohort of HIV-infected 
adults set up in 1995.The death rate observed in patients with CD4 + < 200 cells/µL at 
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enrolment into the EC during the first year (1995/96) was compared with the rate observed in 
the DART study during the first year of follow-up. The study showed that the introduction of 
HAART resulted in a highly statistically significant reduction in HIV related mortality among 
patients with advanced HIV infection in this Ugandan community. These data also showed  
that HAART initiation even in those most severely immunosupressed (CD4+ < 50 cells/µL) 
was still highly beneficial. 
1.4.3 Treatment needs assessment in South Africa 
 
An estimated 1,720,000 HIV infected people in South Africa require treatment as ascertained 
by a recent study using a Markov model of HIV progression in adults, combined with estimates 
of annual new HIV infections from a national AIDS and demographic model. (Johnson, 
2009).Those accessing HAART from the public and NGO sectors by the end of 2005 were 
200,000 people only (Nicoli,2006). 
Table 1.1 An estimated number of people in need of HAART in South Africa, 
Malawi, Mozambique and Swaziland. 
 
South 
Africa  
Malawi  
 
Mozambique  
 
Swaziland  
 
Total population 49 200 000 11 200 000 18 000 000 1 029 000 
Mean adult HIV seroprevalence 10.6%  15% 14% 38% 
Total number of HIV-positive people 5 215 200 900 000 1 400 000 200 000 
Estimated number of people in need 
of HAART 
1 72 1212 170 000 270 000 20 000 
 
{Source: Johnson, 2009} 
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There are several reasons why treatment uptake is low. Low counselling and testing rates may 
be attributed to fear of knowing one’s status and fear of disclosure which may lower treatment 
uptake (Newman, 2007). Lack of laboratory diagnostic services in sub- Saharan Africa is an 
impediment to accurate diagnosis and hence initializing treatment (Petti, 2006). In one 
publication, Erhabor (2006) has shown that the absence of CD4 + count measurements is a 
barrier to the decision to initiate HAART among HIV infected Nigerians.  
 
1.4.4 The value of clinical staging in the decision to initiate treatment  
 
The WHO proposed a staging system in 1994 to assist poorly - resourced countries for 
surveillance and monitoring of HIV disease. Staging is based on clinical findings that guide the 
diagnosis, evaluation, and management of HIV/AIDS, and does not require a CD4+ cell count. 
It is a symptom based classification. This staging system is used in many countries to 
determine eligibility for antiretroviral therapy. Clinical stages are categorized as I through IV, 
progressing from primary HIV infection to advanced HIV/AIDS. These stages are defined by 
specific clinical conditions. For the purpose of the WHO staging system, adolescents and 
adults are defined as individuals aged   ≥ 15 years (WHO, 2005).  
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Table 1.2 The WHO Clinical Staging criteria for HIV/AIDS 
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Source: WHO/HIV/2005.02 
 
Several studies have been done to validate the WHO clinical staging. The majority of the 
studies have suggested that a simple rearrangement of the symptoms and signs in a given 
environment could better predict the eligibility of patients in poorly resourced settings 
(Malamba, 1999). Table 1.2 summarises data from 14 studies which address different aspects 
of validation of WHO clinical staging in predicting eligibility for HAART. The studies assess 
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the relationship between clinical symptoms and signs and either WHO stage, CD4 + count and/ 
or risk of progression to AIDS. 
In a routine service delivery setting in Uganda, Jaffar et al (2008) assessed the ability of the 
WHO clinical staging to accurately identify HIV-infected patients in whom HAART should be 
started. Among 4302 patients, the sensitivity of the WHO criteria to identify eligible patients 
for HAART i.e. CD4 + count < 200 cells/ µL was 52% (95% CI: 50-54). In this setting, a large 
number of individuals (about 50%) would not have received treatment if eligibility to HAART 
was assessed on the basis of WHO clinical staging alone. These data suggest that in settings 
where clinical staging alone is used, many patients would have had treatment deferred until a 
time when they have much more advanced disease. 
 
One author suggested a targeted CD4 + testing only to certain HIV infected individuals in 
WHO stage III whose staging is based on weight loss alone in settings where routine CD4 + 
count is not feasible due to poor resources (Lynen et al 2006). 
In another study (Kagaayi, 2007) the ability of WHO clinical staging to predict CD4 + cell 
counts of 200 cells/µL or less was evaluated among 1,221 patients screened for HAART. The 
sensitivity and specificity of WHO criteria was 51% and 88% respectively. Clinical criteria 
missed half the patients with CD4 + cell counts of 200 cells/µL or less. 
Other authors highlighted the importance of CD 4+ cell measurements for the scale-up of ART 
provision in resource-limited settings (Kagaayi et al, 2007; Jaffar et al, 2008). 
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From the literature reviewed the majority of studies recommended modifications to WHO 
staging by a simple rearrangement of the symptoms and signs in order to accurately predict 
eligibility for HAART initiation in their respective populations (Malamba, 1999; Morpeth, 
2007).
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Table 1.3 Studies analyzing clinical symptoms and signs to predict the need to initiate HAART. 
Author and 
study area 
Year Design Study Population Clinical 
Symptoms 
and signs 
Results Outcome Measure Comment 
(1)TorpeyK,et al 
(Zambia) 
AFRICA 
2009 
 
Retrospectiv
e study 
 
5784 HIV patients 
 
 -29.5% were in stages I and II and had a 
CD 4 ≤ 200 cells/µL 34.6 had a CD 4 
count ≤ 350 cells/µL and were in 
WHO stages I/ II. 
Sensitivity, Specificity  
NPV,PPV 
 
WHO Clinical staging is inadequate to 
identify persons eligible for HAART 
(2) Jaffar et al 
(Uganda) 
AFRICA 
2008  
A 
pragmatic 
effectivene
ss study 
4302 subjects 
screened for ART 
 -About 50% with WHO stage I/II had CD 
4 count < cells/µL 
-the sensitivity and specificity (95% CI) 
of WHO stage III/IV against a CD4 count 
< 200 x 106/l were 52% (50, 54%) and 
68% (66, 70%) respectively. 
Sensitivity and 
specificity 
WHO clinical staging missed 50% of 
patients eligible for ART.      
-Urgent need for greater CD4 count 
prior to initiation of ART to 
accompany the roll-out of ART. 
(3) Kagaayi et al 
(Uganda) 
AFRICA 
2007 Cohort 
Study 
1221 patients of 
whom 65% were 
women 
 Sensitivity was 51% , Specificity was 
88%, the positive predictive value 
was 64%, the negative predictive 
value was 81% 
Sensitivity, Specificity, 
Positive predictive 
value, Negative 
predictive value, WHO 
staging 
Clinical criteria missed half the patients 
with CD4 cell counts of 200 cells/μl or 
less, highlighting the importance of 
CD4 cell measurements for the scale-
up of ART provision in resource-
limited settings. 
(4) Erkose and 
Erturan 
(Turkey) 
EUROPE 
2007 Cross 
Sectional 
64 HIV infected 
out patients 
coming for viral 
load and CD 4+ 
count 
measurements 
Oral 
candidiasis 
No correlation between oral candida 
and declining CD 4 +count. 
CD 4+ counts High prevalence of candida among 
HIV infected patients but not indicative 
of declining CD 4 +count. 
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(5) McGrath 
(Malawi) 
AFRICA 
2007 Cross 
sectional 
11,800 HIV 
seropositive 
adults aged 18-59 
years in selected 
households in 
Karonga DSS site. 
 -WHO staging had a sensitivity 50% and 
specificity 96% in predicting those 
eligible for HAART 
-Those eligible for HAART by WHO 
criteria were 31% and by CD 4 count  
criteria they were 38% 
Sensitivity and 
specificity 
WHO clinical staging alone missed 2/3  
i.e. two thirds 
of those eligible for ART by clinical  
staging and CD 4 count 
(6) Morpeth S. 
(Tanzania) 
AFRICA 
2007 
 
Cross 
sectional 
202 HIV infected 
adult patients  
Mucocutaneou
s 
Manifestations 
The feature most strongly associated 
with CD4 count <200  (p-value 
<0.0001) was the presence of 
mucocutaneous manifestations (72%), 
with a sensitivity of  85% and 
specificity of 63% for predicting CD4 
count <200 cells/µL 
Symptoms & signs,CD 
4 counts  & Laboratory 
parameters(TLC and 
ESR) 
 
 
The presence of mucocutaneous 
manifestations was a strong predictor of 
CD4 count <200 cells/µL and enhanced 
the sensitivity of the 2006 WHO staging 
criteria for identifying patients likely to 
benefit from antiretrovirals. 
(7) Edathodu 
J(Saudi Arabia) 
ASIA 
2007 
 
Retrospecti
ve chart 
review 
191 HIV infected 
patients 
Clinical events 
listed in the 
2005 WHO 
staging  
16/110 (15%) in WHO stage I had 
CD4<200;          3/10(30%) in WHO 
stage II had CD4 + count <200 and 
10-15% of patients at stages III and 
IV had CD4 count >350. 
WHO clinical staging 
and CD4 + counts 
WHO clinical staging criteria missed 
19/191 i.e. 10% of those eligible for 
HAART 
(8) Lynen et 
al.(Cambodia) 
ASIA 
2006 Retrospecti
ve analysis 
of cohort 
data 
648 HIV patients 
in a follow up at 
the Sihanouk 
Hospital 
 9 % i.e.52 patients were wrongly 
identified by WHO criteria to be in 
need of HAART(i.e. had CD4 + 
count  >200) 
sensitivity, specificity, 
and accuracy of the 
2003 WHO criteria to 
start HAART  
Target CD 4 testing to patients in WHO 
stage 3 whose staging is based on 
weight loss alone. 
(9) Teck et al 
(Malawi) 
AFRICA 
2005 Cross 
sectional 
457 HIV positive 
individuals in 
stages 3 and 4 
registered at HIV 
clinic   
TB 413/457 i.e. 90% of Patients in WHO 
stage 3 and 4 had CD4 + count  ≤350 
cells/µL while 10 % had CD 4 
count > 350 cells/µL. 
 
CD 4+ counts 
 
(1) 10 % would be started on ART 
prematurely.(2) WHO staging is an 
appropriate method to predict ART 
eligibility (especially in advanced 
stages) (3) Active or previous TB 
patients in stages 3 and 4 had low CD4 
+  count (<350) thus eligible for ART. 
(10) Costello et 
al (Thailand) 
2004 Cross 839 HIV positive  The WHO guidelines had a sensitivity 
of 34.1% in men and 31.8% in women 
Sensitivity and WHO staging was improved by a 
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ASIA sectional Blood donors to detect persons with CD4 + count  < 
200 
specificity combination of anaemia 
(11) 
Muhammad B 
et al (Tanzania) 
AFRICA 
2003 A sub-
study from 
an ongoing 
cohort 
study 
716 Police 
Officers of whom 
127 were HIV 
positive 
Fungal 
infections, 
herpes zoster, 
Pruritic 
papular 
eruption, 
seborrheic 
dermatitis and 
Kaposi's 
sarcoma  
Mean CD4+ counts  (percentage) :          
KS: 75. Cells/µL (4.0%) 
PPE: 71. cells/µL 
CD 4 counts Pruritic Papular Eruption (PPE) i.e. 
skin rash; and Kaposis Sarcoma (KS) 
are markers of severe 
immunodeficiency due to HIV. 
(12) Malamba 
SS et al   
(Uganda)  
AFRICA     
1999 A Cohort 
Study 
1666 Incident and 
prevalent HIV 
cases followed up 
for 7 years (1990-
1997). 
Unexplained 
prolonged 
fever ,severe 
bacterial 
infection 
,HSV 
,cryptosporidi
osis and  Oral 
candidiasis 
(1)Unexplained prolonged fever and 
severe bacterial infection had survival 
probabilities closer to stage II 
conditions; (2) HSV > 1 month and 
cryptosporidiosis with diarrhoea had 
survival probability closer to stage III 
conditions; (3) Oral candidiasis was 
closer stage IV conditions. 
WHO clinical staging -WHO staging is useful to predict low 
immunity (low CD4 + cells) and 
Survival even without the laboratory 
markers. 
-A simple re-arrangement of a few 
clinical conditions will improve 
prediction of Low CD4 + and thus 
prognosis by the WHO system. 
(13) Kassa et al 
(Ethiopia) 
AFRICA 
1999 Cross 
sectional 
86 HIV positive 
individuals in all 
WHO stages 
Minor weight 
loss, 
pulmonary 
tuberculosis 
23/86(27%) had CD 4 count < 200 
cells/µL BUT only one (1) 
individual was in WHO stage IV. 
CD4 + counts, viral 
load, sensitivity and 
PPV and WHO staging 
-Clinical staging missed 27% eligible 
for ART; -Overall good correlation 
between WHO staging and CD 4 count. 
(14) Aylward 
RB et al 
(Baltimore) 
USA 
1993 Cross 
sectional 
694 HIV 
seropositive IV 
Drug Users 
 The risk of progression to AIDS was 
increased in those in WHO stages 2 
(HR 1.51 CI: 0.6-3.8) and 3(HR 2.39 
CI: 1.4-4.1) compared to those in 
WHO stage 1. 
The hazard for 
progression to AIDS 
This study supports the utility of the 
WHO staging system in predicting 
progression from HIV seropositivity to 
AIDS on the basis of clinical signs and 
symptoms. 
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Table 1.4 Summary of performances of WHO clinical staging and the attempts for 
improvement. 
Study Parameter of WHO clinical staging  performance 
measured 
Suggestion for 
improvement of WHO 
staging criteria 
Jaffar et al,2008  Sensitivity 52% Specificity 68% Urgent need for CD 4 + 
count 
 Morpeth S,2007    Sensitivity 85%   Specificity 63% The presence of 
mucocutaneous 
manifestations 
Lynen,2006 accuracy of the 2003 
WHO criteria to start 
HAART 
 WHO stage III with 
weight loss 
Teck et al, 2005 Proportion of WHO stage 
III/IV with CD4 + count 
≤ 350 cells/µL 
 1-Advanced stage of HIV 
2.Active or previous 
history of tuberculosis 
 Costello et al,2004 Sensitivity 33%  Anaemia,PPE and KS 
Muhammad B,2003 Symptoms and signs 
predicting severe 
immunosuppression 
 PPE and KS 
Malamba,1999 Symptoms and signs in 
WHO clinical axis and 
their corresponding CD4 
+ counts ≤ 200  cells/µL 
 A simple re-arrangement 
of a few clinical 
conditions 
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1.5 Justification 
 
Previous studies have attempted to correlate clinical symptoms and signs with CD4 + counts 
(Malamba, 1999; Kassa, 1999; Morpeth, 2007). A recent study in Johannesburg screened 589 
HIV positive women to determine eligibility for a clinical trial. The screening procedures 
included an assessment of clinical stage of HIV disease using WHO staging criteria (WHO, 
2005) in potential participants; thus providing an opportunity to investigate the association 
between symptoms and signs and CD4 + count. To our knowledge, there are few studies that 
have provided data on people recruited from the community (i.e. not a hospital based data) 
(Jaffar, 2008, McGrath, 2007, Lynen, 2005). 
 
 
 
1.6 Objectives  
  
We undertook this secondary data analysis to:  
1. Determine the distribution of symptoms and signs in women with HIV disease in 
Johannesburg, South Africa. 
2. Determine the distribution of CD4 + count in women with HIV disease in Johannesburg, 
South Africa. 
3. Identify the clinical symptoms and signs which best predict the need to initiate HAART 
(CD4 + count ≤ 200 cells/µL). 
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Chapter 2: Materials and Methods 
 
2.1 Study Design 
 
We conducted secondary data analysis using cross sectional screening data from 589 females 
participating in a randomized   controlled clinical trial in HIV positive women (Delany, 
2009). 
2.2 Study Population 
 
2.3.1 Inclusion criteria 
The trial included women who were: 18 years of age and above, HIV seropositive on two 
independent rapid tests, resident in Johannesburg for the period of the study, consenting to 
participate in the study and who had their CD4 + counts measured. 
2.3.2 Exclusion criteria 
The trial excluded women who were: pregnant, involved in another ongoing trial, epileptic, 
not HSV-2 seropositive, could not adhere to visit schedule, had > 6 episodes of genital 
herpes per year, had genital urinary disease (GUD) >1 month and those who could not 
undergo a clinical evaluation.(Fig. 2.1) 
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Fig. 2.1 A flow chart showing how the sample was derived for analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3 Clinical Procedures  
 
Potential participants were invited from local clinics and the surrounding community to 
attend the study clinic at RHRU at 17 Esselen Street Clinic in Johannesburg, for voluntary 
counselling and testing for HIV after giving written informed consent. Those who met the 
589 Screened for trial 
Eligible for the 
clinical trial 
Included in the analysis 
526 
No CD 4+ data - Ineligible 
8 – epileptic 
7 – pregnant 
6 - not HSV-2 seropositive 
4 – could not adhere to visit schedule 
2 – had > 6 episodes of genital herpes per 
year 
2 – had GUD >1 month and planning to be 
pregnant 
2 – could not undergo clinical evaluation 
Eligible for treatment 
32 – Already in stages III and IV and therefore 
referred for treatment. Also no CD 4+ data 
NO 
YES 
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eligibility criteria were then enrolled in the main clinical trial. At screening, participants 
were interviewed and examined by experienced doctors and nurses on specific HIV- related 
features. The doctors and nurses recorded the findings on a standardized checklist of possible 
HIV- related signs and symptoms which was based on the WHO criteria for clinical staging 
for HIV (Appendix 1) (WHO,1994). Some additional clinical features (e.g. fatigue or 
participant looking tired, dehydration etc) which are not strictly in the WHO clinical criteria 
were recorded by clinicians during physical examination. These features are incorporated in 
this analysis to examine their usefulness in predicting the outcome variable (i.e. CD4 + 
counts).  
According to the trial protocol, blood was drawn for CD4 + count measurement in those who 
were in WHO clinical stages I/II. Those that were in WHO stages III/IV were referred for 
treatment immediately. 
2.4 Laboratory Procedures  
 
CD4 + counts were determined using the pan leucogating method (Wilja, 2002). All blood 
specimens were collected for processing, testing and/or storage at the Contract Laboratory 
Services (CLS) which is located within the University of the Witwatersrand Medical School 
at Parktown (approximately 5-10 minutes drive from the study clinic) in Johannesburg. 
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2.5 Statistical analysis 
 
The data set was analysed using STATA 9. Descriptive statistics were used to summarize the  
distribution of symptoms and signs and CD 4 + counts among the study population. 
 
2.5.1 Tests used to determine the predictive value of WHO clinical staging system. 
 
Sensitivity, specificity, positive predictive values, negative predictive values, odds ratios and 
their 95% confidence intervals were used to determine the reliability of the WHO staging 
system  in predicting the CD4 + count ≤ 200 cells/µL and < 350  cells/µL. Table 1.3 shows 
the categories of parameters and the subsequent formulae (Katzenellenbogen, Joubert and 
Abdool-Karim, 1997). 
Table 2.1 Formulae to calculate the epidemiological diagnostic tests 
 CD 4 <= 200 CD 4 > 200 Total 
WHO stage III,IV A B A+B 
WHO stage I,II C D C+D 
Total A+C B+D A+B+C+D 
 
Sensitivity 
Sensitivity was defined as the proportion of CD4 + counts ≤ 200 cells/µL classified as WHO 
stage III/IV.  
Sensitivity = A /A+C x 100 
Also the cii command in stata was used to give both the sensitivity (given as mean) and its 
95% CI as: cii (A+C) A, where (A+C) = total binomial events, A = number of observed 
successes 
Specificity 
Specificity was defined as the proportion of CD4 + count > 200 classified as WHO stage I/ II 
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Specificity = D/B+D x 100 
Also the cii command in stata was used to give specificity (given as mean) and the 95% CI 
across the mean 
Positive Predictive value (PPV)  
PPV was defined as the proportion of WHO stage I/II that have CD4 + count ≤ 200 cells/µL 
PPV= A /A+B x 100 
Also the cii command in stata was used to give the positive predictive value (given as mean) 
and the 95% CI across the mean 
Negative Predictive Value (NPV)  
The NPV was defined as the proportion of WHO stage III/IV that have CD4≥200 cells/µL 
NPV= D /C+D x100 
Also the cii command in Stata was used to give the positive predictive value (given as mean) 
and the 95% CI across the mean 
2.5.2 Regression analyses 
The assessment of the diagnostic value of the WHO criteria to predict CD4 + count (above or 
below 200 cells/µL) was evaluated using univariate logistic regression. The strength of 
association between symptoms and signs (clinical indicators) and CD 4 + count ≤ 200 
cells/µL was determined by odds ratios and 95% confidence intervals. Adjusted analysis was 
performed to identify the symptoms and signs that were significantly associated with the CD 
count ≤ 200 cells/µL at a significance level of 0.2. These significant symptoms and signs at a 
univariate model were used to predict CD4 + ≤ 200 cells/µL by fitting multivariate models 
using logistic regression. The model adequacy was tested using estat gof command. The 
link-test was used to test for the presence of interaction among the symptoms and signs that 
persistently remained significantly predicting CD4+ count < 200 cells/µL at a multivariate 
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level. The above analysis was repeated to determine whether these indicators were still 
useful if the criteria for treatment were raised to CD4 + count ≤ 350 cells/µL. The remaining 
symptoms and signs not significantly predicting CD4 + count ≤ 200 or ≤350 cells/µL at 
univariate analysis were excluded from the analysis of sensitivity, specificity, positive and 
negative predictive values. If such statistical tests were performed on these symptoms and 
signs, they would neither have shown any significant results nor be able to correlate their 
presence with the CD 4 count ≤ 200 or ≤350 cells/µL. 
 
2.6 Study sample size and power 
 
Hypothesis:  
We hypothesized that the use of WHO clinical staging system alone is feasible and 
appropriate to identify HIV positive asymptomatic women eligible for HAART (i.e. CD4 + 
count ≤ 200 cells/µL) in a South African setting.  
The study sample size was determined by the method of “Estimated sample size for two-
sample comparison of means” where a comparative study (Post, 1995) was considered. The 
Evaluation of WHO staging performance study  had a mean CD4 + count of 455 cells/µL 
and a standard deviation and 252 while the  study by Post (1995) had mean CD4 + count of 
389 cells/µL and standard deviation and 161 respectively. The sample sizes of the former 
and the latter studies had a ratio of 3.5. Significance level of 0.05 was assumed; giving a 
required minimum sample size of 242 participants in order to have a power of 0.9708 to 
detect the differences between those with CD4 + count < or ≥ 200 cells/µL. Although this 
study is now a secondary (post-hoc) data analysis, the study power of 0.9708 is strong 
enough to test our hypothesis. 
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2.7 Ethical Considerations 
 
Informed consent in the language of the patient was sought prior to study procedures. 
Patients were consulted in the key elements of the informed consent process viz. volunteer, 
option to withdraw without prejudice and risk benefits. Patients therefore filled and signed 
written informed consent at screening phase of the main trial. Confidentiality of individual 
study participants was observed by using unique identification numbers. 
The investigator of this study obtained an approval from RHRU to use the data collected at 
the screening phase of the main trial. The protocol of this study was submitted to the 
University of the Witwatersrand Human Subjects Research Ethics Committee for clearance. 
The protocol was unconditionally approved by the HREC and given the ethical clearance 
reference number M080339. 
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Chapter 3: Results 
 
3.1 Identification of the patient population included in the analysis 
 
A total of 589 HIV infected women completed screening visits. Of 589 women assessed, 526 
were assessed as clinically WHO stages I/II and 32 were in stages III/IV. Thirty one (31) 
were not assessed further because they did not meet other trial eligibility criteria (Fig.2.1).  
 
3.2 Characteristics of Participants 
 
Overall 73 (13%) of 526 participants had CD 4+ count < 200 cells/µL while 136 (26%) of 
526 had CD 4 + count < 350 cells/µL. By stage 13% in stage I/II had CD 4+ <200 cells/µL 
compared to 3(50%) of 6 participants while 26% in stage I/II had CD 4+ < 350 cells/µL 
compared to 2 (33%) of 6 participants in stages III/IV. The mean age of all participants was 
32, standard deviation 7 and the minimum and maximum age of 18 to 58 years respectively.  
In this study population, the median time since diagnosis for all participants was 0.76 years 
(IQR: 0.09 - 3.00) i.e. 9 months. Among all patients (N=526) the most common symptoms 
were pain or difficulty in swallowing (dysphagia and possible oesophageal candidiasis) 
(18%) , cough for more than one month (8%) , and previous hospitalization in the past 
twelve months (10%). The most common causes for hospitalization in the preceding twelve 
months were obstetric and gynaecological problems (53%), pneumonia (14%), and 
tuberculosis (12%). Less frequently reported symptoms were diarrhoea (6%) and fever (4%). 
Overall, on examination the most common finding was swollen glands in the neck or 
armpits. The median CD4 + count overall was 403 cells/µL (IQR: 273-586). Table 3.1 
summarises patient characteristics by WHO stage. 
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Table 3.1 indicates that the majority of study participants were in the early stages of HIV 
infection. Those in clinical stages I/II had been diagnosed more recently and had a higher 
median CD4 + count than those in clinical stages III/IV. 
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 Table 3.1 Characteristics of participants and clinical profile 
Characteristic WHO Stage I/II    N =520 
 N (%) or Median(IQR) 
WHO Stage III/IV N=6  
N   (%) or Median(IQR) 
Median time since HIV diagnosis (years)  0.8(0.1-3.0) 1.7 (0.1-1.8) 
Symptom history 
Pain or difficulty with swallowing 
 Hospitalized in the previous 12 months 
 Cough > 1 month  
 Night sweats > 1 month 
 Headache > 1 month 
  
Confined to bed  > 50% the day time  
(Substantial unintentional weight loss ≥ 10% 
body weight 
Diarrhoea > 1 month (i.e.  ≥ 3 loose 
stools/day) 
 Persistent genital or oral sores >1 month 
 History of Tuberculosis 
 Generalized body rash 
Examination findings 
Swollen glands in the neck/axillae 
 Lymphadenopathy 
 Oral thrush (candida) 
 Zoster (shingles) 
Participant looks tired 
 Generalized skin rash 
 
96(18)   
51(10) 
42(8) 
25(5) 
24(5) 
 
25(5) 
17(3) 
 
8(2) 
7(2) 
27(5) 
34(7) 
 
65(13) 
40(8) 
21(4) 
22(4) 
10(2) 
12(2)           
 
1(17) 
0(00) 
1(17) 
1(17) 
1(17) 
 
1(17) 
2(33) 
 
1(17) 
2(33) 
1(17) 
3(50) 
 
2(33) 
0(00) 
2(33) 
1(17) 
0(00) 
1(17) 
Median CD 4+ count  [cells/µL (IQR)] 405(279 -588) 211
 
(174 -248) 
CD4+ count (cells/µL )     
< 200
 
70(13) 3(50) 
200-350
 
134(26) 2(33) 
>350
 
316 (61) 1(17) 
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3.3 Patients with CD4 + count < 200 cells/µL while in WHO clinical stages I and II 
 
Seventy three (14 %) of the study population had CD 4+ count < 200 cells/µL. 
Table 3.1 indicates that 70 (13%) of 520 women were in WHO clinical stages I and II and 
they had CD4 + count < 200 cells/µL. One hundred thirty four (26%) of 520 women who 
had CD4 + counts in the category < 350 cells/µL would become eligible for ARV if 
treatment guidelines were to change. 
 
3.4 Diagnostic value of WHO clinical criteria 
 
We assessed the diagnostic value of WHO staging in this population. The results are 
presented in table 3.2. Table 3.2 shows a low sensitivity of WHO clinical staging in 
predicting CD4 +count < 200 cells/µL and < 350 cells/µL but a high specificity. It also 
shows a higher specificity and a positive predictive value from a CD 4 + counts 200 to 350 
cells/µL. However, confidence intervals are wide because of small numbers of the patients 
with CD4 + counts < 200 and also ≤ 350 cells/µL. 
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Table 3.2 The sensitivity, specificity, positive (PPV) and negative predictive values 
(NPV) of WHO clinical stage against CD4 + counts for the assessment of eligibility for 
HAART. 
 CD4 count × 
10
6
/l (number  
of subjects) 
Total Sens  Spec  PPV 
 
NPV 
 
WHO stage <200 ≥200                  [Percent (95% CI)] 
 
 4(1-12)    99(98-100)   50(12-88)   87(83-89) 
III,IV 3 3 6 
I,II 70 450 520 
Total 73 453   
 <350 ≥350 
III,IV 5 1 6  2(1-6)    99(98-100)      83(36-99)       61(57-65) 
I,II 203 317 520 
Total 208 318 
 
Table 3.2 indicates that the likelihood of identifying an HIV patient with WHO clinical stage 
I/II and having CD4 + counts ≤ 200 cells/µL is 4% while identifying a patient having CD4 + 
count ≤ 350  cells/µL is 2%. 
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Table 3.3 The symptoms and signs predictive of the need to start HAART treatment (CD4 + count ≤ 
200 cells/µL) 
 
Clinical Indicator   CD4 
<200 
(%) 
N=73 
CD4 
≥200 
(%) 
N=45
3 
Measure of 
Association  
OR   
(95% CI) 
p-
value 
Adjusted 
Measure of 
Association 
OR(95%CI) 
p 
value 
On History: 
Pain or difficulty with swallowing 
 
9 (13) 
 
88(2
0) 
 
0.6 (0.3-1.2) 
 
0.173 
 
 0.4(0.2-1.2) 
 
0.095 
Fever > 1 month 3 (4) 10(2) 1.9 (0.5-7.2) 0.329 0.3(0.1-4.6) 0.415 
Cough > 1 month 11 (15) 32(7) 2.5 (1.2-5.3) 0.014   2.6(1.2-5.6) 0.017 
History of TB 7 (10) 21(5) 2.2 (0.9-5.4) 0.081  1.7(0.5-5.7) 0.355 
Night sweats > 1 month 5 (7) 21(5) 1.5 (0.6- 4.2) 0.405 0.8(0.2-4.4) 0.866 
History of Generalized body 
rash 
10(14) 27(6) 2.5 (1.2- 5.5) 0.018 2.9(1.3-6.7) 0.011 
Persistent genital or oral sores 
>1 month 
3 (4) 6(1) 3.2 (0.8-13.3) 0.102  0.6(0.1-13.6) 0.725 
Diarrhoea  > 1 month  3 (4) 6(1) 3.2 (0.8-13.3) 0.102  4.9(1.4-50.7)           0.179 
On Examination:       
Oral thrush (candida) 7(10) 16(4) 2.9 (1.2-7.4) 0.022 2.6(1.1-6.9)   0.047 
Swollen glands in the neck or 
axillae 
11(15) 56 
(12) 
1.3 (0.6-2.6) 0.492 0.9(0.4-2.5) 0.955 
Substantial unintentional wt loss  10 (5) 15(3) 1.7 (0.6-5.4) 0.228 1.3(0.1-45.6) 0.873 
Fatigue (general body malaise) 4 (6) 6(1) 4.4 (1.2-15.9) 0.025 4.9(1.4-18.1) 0.015 
Pallor 2 (3) 4 (1) 3.2 (0.6-17.8) 0.184 1.1(0.1-26.9) 0.931 
Dehydration 2 (3) 1(1) 12.9 (1.2-
144.3) 
0.038 14.6(1.3-
163.8)                      
0.030 
Generalized skin rash 5 (7) 8 (2) 4.2 (1.3-13.3) 0.014 3.6 (1.1-11.8)    0.034 
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3.5 Symptoms and/or signs associated with CD4 + count < 200 and < 350 cells/µL. 
 
We conducted an analysis to determine the symptoms and signs that predict the need for 
HAART initiation in this study population (Table 3.3). In a univariate logistic regression 
analysis, cough > 1 month, history of tuberculosis, history of generalized body rash, 
persistent genital or oral sores > 1 month, diarrhoea > 1 month, oral thrush, herpes zoster, 
general body malaise, dehydration and generalized skin rash were associated with CD4 + 
count < 200 cells/µL. The significant symptoms/signs persistently predicting CD4 + count < 
200 cells/µL at a multivariate model were dehydration (OR= 14.6), skin rash (OR= 3.6), 
candida (OR = 2.6), cough>1 month (OR= 2.6) and history of generalized body rash (OR= 
2.9). The model was adequate and there were no interaction terms detected. 
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Table 3.4. The distribution of CD 4 + counts at a cut – off ≤ 350 cells/µL and clinical indicators 
that remained significant in predicting CD4 count < 350 cells/µL. 
 
Clinical Indicator   CD4 
<350 
(%) 
N=73 
CD4 
≥350 
(%) 
N=453 
Measure of 
Association  
OR   
(95% CI) 
p-
value 
Adjusted 
Measure of 
Association 
OR(95%CI) 
p 
value 
On History: 
Pain or difficulty with swallowing 
34 (16) 63 (20) 0.8 (0.5-1.3) 0.329 0.7(0.4-1.2) 0.157 
Fever > 1 month 7 (3) 6 (28) 1.8 (0.6-5.5) 0.288 0.6(0.1-3.2) 0.542 
Cough >1 month 23 (11) 20 (6) 1.9 (1-3.5) 0.050 1.8(0.8-4.4) 0.172 
History of TB 17 (8) 11(3) 2.5 (1.1-5.4) 0.021 2.4(1.1-5.2)  0.034   
Night sweats > 1 month 10 (5) 16 (5) 1 (0.4- 2.1) 0.918 0.6(0.2-2.1) 0.464 
History of generalized body rash 18 (9) 19 (6) 1.5 (0.8- 2.9) 0.236 1.2(0.4-3.1) 0.758 
Persistent genital oral sores >1 
month 
4(2) 5(2) 1.2 (0.3-4.6) 0.757 0.2(0.1-3.7) 0.293 
Diarrhoea  > 1 month  5(2) 4(1) 1.9 (0.5-7.3) 0.326 1.3(0.2-10.8) 0.782 
On Examination:       
Oral thrush (candida)   16 (8) 7 (2) 3.7 (1.5-9.2) 0.004 3.2 (1.2-7.9)     0.015 
Swollen glands in the neck or 
axillae 
30 (14) 37 (12) 1.3  (0.8-2.2) 0.338 1.1(0.6-2.2) 0.706 
Substantial unintentional wt loss  10 (5) 9 (3) 1.8 (0.7-4.4)   0.228 1.8(0.4-7.4) 0.401 
Fatigue (general body malaise) 6(3) 4(1)       2.3(0.7-8.4)                        0.191 1.2(0.2-9.5) 0.833 
Pallor 4(2) 2(1) 3.1(0.6-17.1)     0.193 2.3(0.1-36.9) 0.558 
Herpes Zoster 6 (8) 17 (4) 2.3 (0.9-6.1) 0.086 0.2(0.1-2.3) 0.200 
Generalized skin rash   10 (5) 3 (1) 5.4 (1.5-19.7) 0.012 4.5 (1.2-17.0)    0.026 
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We again conducted an analysis to determine the symptoms and signs which where still 
useful in predicting the need for treatment at higher CD4 + counts such as CD4 +  count ≤ 
350 cells/µL, a threshold level recently recommended by WHO for starting HAART (Table 
3.4). At a significance level of 0.2 in a univariate analysis, cough for more than one month, 
history of tuberculosis, generalized body rash, oral thrush, general body malaise, pallor, 
herpes zoster and generalized skin rash were the symptoms and signs predicting CD4 + count 
< 350 cells/µL. The significant symptoms/signs persistently predicting CD4 + count < 350 
cells/µL at a multivariate model were, candida (OR= 3.2) and generalized skin rash (OR = 
4.5) and history of tuberculosis (OR= 2.4). The final model was found to be adequate with 
no interacting symptoms and signs in predicting CD4 + count 350 cells/µL. 
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3.6 Sensitivity and specificity of modified clinical staging 
 
We conducted an analysis of sensitivity and specificity on clinical features that predicted 
CD4 + count < 200 and < 350 cells/µL on adjusted analyses. 
Table 3.5 Sensitivity, Specificity, PPV and NPV for the indicators for multivariate 
significant variables at CD4 + count cut-off 200 cells/µL and 350 cells/µL. 
                                                                        
Clinical 
Indicators 
CD 4 Count  (no. of subjects) 
<200 (N=73)          >200(N=453)    
Sensitivity 
[Percent(95
% CI)] 
 
Specificity 
[Percent(95
% CI)]          
         
PPV 
[Percen
t(95% 
CI)]    
  NPV 
[Percent(
95% CI)] 
 
Generalized 
skin  rash 
5 (7%)               8 (2%)
  
7(2-15) 98(97-99) 38(14-
68) 
88(84-
90) 
Oral thrush 7(10%)             16(4%) 10(3-19) 96(94-98) 30(13-
53) 
87(84-
90) 
Dehydration 2(3%)               1(1%) 3(1-9) 99(98-
99.9) 
67(10-
90) 
86(83-
89) 
 <350 (N=208)       >350(N=318)                    
Generalized 
skin rash 
10 (5%)              3 (1%) 5(2-9) 99(97-
99.8) 
76(46-
95) 
62(57-
66) 
Oral thrush 4 (2%)                 6 (2%) 2(1-5)  98(96-99)  40(12-
74)  
60(56-
65) 
History of 
TB 
17(8%)               11(3%) 8(5-13) 97(94-98) 61(41-
78) 
62(57-
66) 
 
Table 3.5 shows low sensitivity and low positive predictive values of the symptoms and 
signs that predict CD4 + count < 200 cells/µL. The specificity and negative predictive values 
were fairly high. These clinical features were significant on adjusted analysis. Oral thrush 
(candida) has the highest sensitivity (10%) of the three clinical features. Table 3.5 further 
shows generally a low sensitivity of the clinical features in predicting CD4 + count < 350 
cells/µL. The positive predictive values increased at the CD4 + count threshold of 350 
 37 
 
cells/µL while the NPV decreased in comparison to those of the CD4 + count threshold of 
200 cells/µL. Sensitivity decreased for generalized skin rash while specificity increased.  
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Chapter 4: Discussion 
 
We set out to investigate which signs and symptoms were commonly associated with HIV 
infection that could be used to best predict immunosuppression among asymptomatic HIV 
infected women in South Africa, and therefore the need for HAART. We hypothesized that 
the use of WHO clinical staging alone is feasible and appropriate to determine those eligible 
for HAART in a South African setting. Our hypothesis was not confirmed. Overall there was 
a very low sensitivity and specificity of the WHO clinical staging in identifying those in 
need of HAART initiation. 
4.1 Percentage of HAART eligible patients not detected by WHO criteria 
 
This analysis adds more information on the currently available limited data on how well the 
WHO HIV clinical staging criteria performs in correctly identifying patients needing 
HAART.  Our data have shown that WHO clinical staging is a poor substitute for CD4 + 
count determination. 
 In this study of HIV positive women recruited from the community, 98.8% were in WHO 
clinical stages I and II and had a median CD4 + count of 405 cells/µL (IQR: 279, 588).These 
results reveal that even in this relatively healthy group 14% had CD4 + count < 200  cells/µL 
and required treatment. They would have been deferred HAART treatment on the basis of 
WHO staging alone. A recent study (Kagaayi et al, 2007) conducted in Rakai, Uganda, 
showed that 49% of patients with CD4 + count < 200 cells/µL were classified as WHO stage 
I/ II. Other studies from Uganda and Ethiopia have had similar findings where between 27-
49 % of patients assessed as WHO stage I/II had CD4 + count < 200 cells/µL and would not 
have been started on treatment on clinical assessment alone (Kassa, 1999; Jaffar, 2008).This 
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could be because of low symptom recognition, other concurrent illnesses, lack of access to 
diagnosis and poor training of health care providers. 
 
4.2 Performance of WHO criteria to predict initiation of HAART   
This study showed that WHO clinical staging had sensitivity, specificity, PPV and NPV of 
4%,99%,50% and 87% respectively in predicting CD4 + T-cell count <200  cells/µL. Several 
studies (French,1996; Costello,2005; Martinson,2005; Kagaayi,2007 and Jaffar,2008) also 
found a low sensitivity of 76%; 31.8%; 24%; 51%; and 52%, respectively in various settings, 
all indicating weakness of WHO clinical staging to accurately predict initiation of HAART 
in poorly-resourced countries. 
In the study by French (1999) he found 76% sensitivity and 65% specificity for predicting a 
CD4+ T-cell count <200 cells/µL, positive predictive value of 56%, negative predictive 
value 78%.These results are similar to the current study in terms of PPV and NPV. The low 
sensitivity in our current analysis can best be explained by the fact that most of our patients 
were asymptomatic and were predominantly in the early WHO clinical stages; and the fact 
that CD 4 + counts were taken from those who were in WHO clinical stages I/II as per 
protocol of the main clinical trial. 
 
Another study done in Uganda (Jaffar et al, 2008) found that the sensitivity, specificity, 
positive and negative predictive values predicting CD 4 + T-cell count <200 cells/µL was 
found to be 52% (95% CI 50, 54%), 68% (95% CI 66, 70%), 64 % and 56% respectively. A 
bigger sample size for the study by Jaffar (N= 4302) could explain a narrower confidence 
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intervals as opposed to our rather smaller sample size (N=526) which led to our wider 
confidence intervals and hence less precision.  
A study done in Thailand (Costello et al, 2005) among women found that the December 
2003 WHO guidelines had a sensitivity of 31.8% to detect persons with a CD4 + count < 200 
cells/µL in this HIV-infected population. This is clearly a low sensitivity as well. However 
the use of a TLC <1500 cells/µl or TLC < 2000 cells/µL combined with anaemia or WHO 
stage II infection doubled the sensitivity to detect persons with a CD4 count < 200 cells/µL 
(63.0% in men, 68.2% in women) with less than a 6 % decrease in specificity. The Costello 
study combined the various threshold points of TLC (TLC < 1500 cells/µL or TLC <2000 
cells/µL or < 1800 cells/µL) combined with anaemia and BMI to determine the sensitivity 
and specificity of WHO staging in predicting CD4 + count < 200 cells/µL and < 350 
cells/µL. This combination doubled the sensitivity of WHO criteria to predict CD 4 < 200 
cells/µL and < 350 cells/µL.Our data, in contrast, utilized the WHO classification criteria 
(symptoms and signs) only to determine CD4 + count < 200 cells/µL and < 350 cells/µL and 
had a low sensitivity though high specificity, indicating the limitation of WHO staging for 
screening people who are clinically well as compared to those who are debilitated for 
treatment eligibility.  
Our data have shown that the WHO staging is useful for identifying those with obvious 
symptoms and signs (i.e. clinically ill) who need treatment but not so useful for clinically 
well people who would also benefit from treatment. It thus follows from our data that clinical 
assessment alone among the HIV positive from the general population has proved to be weak 
in identifying eligible persons for HAART. This is in agreement with earlier reports that 
suggested a combination of routine, affordable parameters like TLC, haemoglobin and BMI 
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to the clinical parameters to further improve the sensitivity and specificity of WHO clinical 
staging system. (Costello et al, 2005).  
Kagaayi et al (2007) in Uganda also showed that the sensitivity to predict CD4 + count of 
200 cells/µL or less was 51% and specificity was 88 %. The positive predictive value was 64 
% and the negative predictive value was 81%.Clinical criteria missed half the patients with 
CD4 + cell counts of 200 cells/µL or less, highlighting the importance of CD4 + cell 
measurements for the scale-up of ART provision in resource-limited settings. This is another 
evidence for the weakness of such a tool in identifying those eligible for treatment. Of 
careful note here is that Kagaayi analysed data on patients seen in the Rakai Health Sciences 
Programme (RHSP) community-based ART programme to assess whether WHO clinical 
stages III/IV could be used to identify individuals with CD4 + cell counts of 200 cells/µL or 
less. This implies that these clinical stages were already advanced (i.e. stages III/IV) as 
opposed to our data which had patients in clinical stages I/II. 
Martinson N et al (2005) conducted a study in primary healthcare facilities in South Africa 
which showed that 24% of patients classified as WHO stage I and 46% classified as stage II 
had CD4 + cell counts of 200 cells/µL or less. A substantial proportion of stages I and II 
cases would not have been initiated on ART if therapy was based on clinical criteria alone. 
This finding is a further evidence of the inability of WHO clinical criteria alone in 
identifying asymptomatic infected persons from the general community who are eligible for 
HAART.  
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4.3 Symptoms and signs significantly predicting HAART initiation (i.e. CD 4 < 200 
cells/µL) according to the current South African guidelines 
 
In this study the identified clinical indicators for CD4 + count < 200 cells/µL after adjusting 
for all factors were generalized skin rash, dehydration and oral thrush (candida). We note 
that patients likely to seek care for these conditions may not know their HIV status; and these 
conditions are strong predictors of need for treatment. Amirali et al (2004) also identified 
exactly the same symptoms and signs among hospitalized HIV positive patients in Hindu- 
Mandal Hospital in Dar es Salaam, Tanzania, consistent with our findings in these women 
from the general community in Johannesburg. South Africa.  
                                                                                                                                                                                    
The finding of a non - specific generalized skin rash on examination was associated with low 
CD4 + count (OR= 4.2, 95% CI:1-13).This is consistent with a study by Bakari et al (2003) 
among 716 police officers in Dar es Salaam,Tanzania.Bakari found that among 191 police 
officers, 26.7% had at least one skin diagnosis. HIV-infected police officers had significantly 
higher prevalence of skin diseases than HIV-uninfected police officers (42% vs 26 %, p = 
0.002).The authors also found that PPE, herpes zoster and KS strongly suggested underlying 
HIV-related immunodeficiency. 
Mbuagbaw et al (2004) studied the patterns of skin manifestations and their relationships 
with CD4 + counts among 384 HIV/AIDS patients in Cameroon. The authors found that up 
to 264 (68.8%) patients presented with at least one type of skin problem. Generalized 
prurigo, oral candidiasis, herpes zoster, and vaginal candidiasis were the most common skin 
problems associated with mean CD4 + count (128 ± 85 cells/µL) and mean viral load 
(79,433 copies/mL) (P < 0.001).Generalized skin rash was associated with lower mean CD4 
+ cell counts (78 ± 66 cells/µL, P < 0.001). 
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 A study by Machekano et al (2002) among 447 HIV – infected men in Zimbabwe to 
determine the clinical signs and symptoms in the assessment of immunodeficiency in men 
with HIV infection in Harare showed that skin infections and enlarged lymph nodes had the 
strongest prognostic effect in all the models considered.  In the current study generalized 
skin rash remained significant at both CD4 + count threshold of 200 and 350 cells/µL 
confirming its importance in immunosupressed persons. In the same study Machekano 
(2002) indicates that skin infections were more than twice as likely to be reported in patients 
with CD4 + counts < 200 cells/µL compared to patients with CD4 + cell counts >200 
cells/µL.Skin manifestation as a generalized rash is a strong marker of severe 
immunosuppression in the multivariate models in the current study at both thresholds of CD 
4 + counts 200 and 350 cells/µL. 
The possible explanation for skin manifestation being common at low CD4 + count is due to 
altered normal flora along side immunodeficiency. Other mechanisms could be auto immune 
phenomena like vitiligo, alopecia, etc which are predominantly due to immune dysregulation 
seen in HIV at low CD4 + count (Cho M, 1995). The other explanation could be a systemic 
immune dysfunction, as seen in HIV infection, where the influx of CD4 + lymphocytes to 
the perifollicular regions of skin when the CD4/CD8 ratio is low leads to skin inflammation 
(Stewart, 1993). 
Dehydration was an additional clinical feature not strictly in WHO criteria but was found to 
be significant in predicting CD4 + count < 200 cells/µL in this study population. Although it 
featured in our adjusted analyses it was based on a small number of patients (4 out of over 
500). The possible explanation for dehydration in HIV infection is due anorexia, dysphagia 
and chronic diarrhea. 
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Oral thrush was found to predict both CD4 + counts < 200 and < 350 cells/µL.It is a marker 
of HIV infection that is bound to occur especially during advanced stage of 
immunosupression (Carré et al, 1998). Oropharyngeal candidiasis is the most common 
fungal and opportunistic infection in human immunodeficiency virus - infected individuals, 
affecting nearly 90% of subjects at some stage during the course of HIV disease progression 
(De Repentigny et al, 2004). 
In this study oral thrush was identified to predict CD4 + counts at both thresholds of < 200 
and < 350 cells/µL.This is concordant with other reports (Carré et al 1998; Munoz-Perez, 
2002 and Sud et al, 2009). In the study by Carré among homosexual men, the occurrence of 
oral thrush at a CD 4 + count > 200 cells/µL signifies that oral thrush remained an important 
risk factor, underlining the predictive value of clinical signs at CD4 + count higher than 200 
cells/µL. In another study by Erkose (2007) it was reported that 53/64 i.e. (83%) HIV 
infected patients were colonized by oral candida in Istanbul, Turkey. This study shows no 
correlation between CD 4 + count and oral candidiasis although they report a high 
prevalence of oral candida colonization (83%) in their study population.   However he noted, 
from his study of 64 HIV individuals, that the failure to show an association may be 
explained by his small sample size and hence less statistical power.  
In one study in Zimbabwe, oral candidiasis was the most common lesion diagnosed in nearly 
one quarter of 320 HIV-infected women. It was also shown that of those with oral 
candidiasis, one-third of them had a CD4 + count < 200 cells/µL. (Chidzonga et al, 2008). 
Mbuagbaw et al (2004) also found that in Cameroon oral candidiasis was associated with CD 
4 count < 200 cells/µL (p<0.02). 
So far these studies show contrasting findings with regard to relationship between CD 4+ 
counts and oral thrush. The most important message here, however, is that as oral thrush 
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occurs in both patients with CD4 + > 200 and as well as in CD 4+ < 200 it lacks specifity as 
a sign of AIDS. Thrush (candidiasis) is seen at these levels of CD 4 + counts because 
patients often develop dysregulated cytokine production, a dysfunction in the local oral 
immunity, superimposed on a weakened cell-mediated immunity and depletion of CD4 + T 
cells (Egusa,2008). The role of defective dendritic cells and CD4 + T cells in impaired 
induction of protective immunity has been documented as the pathogenesis of thrush (de 
Repentigny, 2009). 
 
4.4 Symptoms and signs significantly predicting HAART initiation (i.e. CD 4 < 350 
cells/µL) according to the new WHO recommendation 
 
Generalized skin rash, history of tuberculosis and oral thrush were the symptoms and signs 
that predicted CD4 + counts < 350 cells/µL after a multivariate analysis. It is observed that 
generalized skin rash remained significant at both CD4 + count thresholds of 200 and 350 
cells/µL. This finding signifies that dermatological manifestations are an early and important 
clue of significant immunosupression (Bakari et al 2003). 
 
History of TB was an important predictor if treatment is to be initated at higher CD4 + count 
levels. HIV infection and related opportunistic infections, particularly tuberculosis and upper 
respiratory tract infections, have become the leading cause of death in much of sub-Saharan 
Africa (Machekano R, 2002).Machekano also noted that currently, most health care 
providers have limited access to laboratory diagnosis and monitoring of HIV infection. They 
rely heavily on clinical manifestations of the disease.  
 46 
 
Literature shows a challenge of making a diagnosis of tuberculosis at the CD4 + cell count 
threshold of < 200 cells/µL (Mtei, 2005).This analysis has indicated a history of tuberculosis 
to predict CD4 + count < 350 cells/µL. This is a further evidence of the relative easiness of 
making a diagnosis of TB at a CD4 + count >200 cells/µL. A study conducted in Malawi 
(Zachariah R et al, 2005) showed that pulmonary TB was present in 98% (51/52) among 
HIV positive individuals presenting with and without WHO defining diseases, among those 
having CD4 + count < 350 cells/µL. Tuberculosis was also noted by another researcher in 
Tanzania (Mtei, 2005) to be present while CD4 + count was still above 200 cells/µL, a 
finding that is concordant with this study. Narain (2004) showed that HIV is considered to be 
the most important risk factor to progression to active TB among those infected both with 
TB and HIV. As a result, TB is the most common life threatening opportunistic infection 
associated with HIV, and the biggest cause of death among patients with HIV. The deadly 
relationship between HIV and TB results from each potentiating the effect of the other. In the 
context of this analysis, the relationship between TB and HIV is an important finding. 
4.5 Practical Implications for Screening for a History of TB. 
Our data has shown that cough > 1 month was significant in predicting CD4 + count < 200 
cells/µL while a history of TB predicted CD4 + count < 350 cells/µL.HIV infection is 
therefore a risk factor for TB disease (Tribble,2009). The implications for screening for a 
history of TB are for diagnosis and treatment among TB/HIV co-infected. The following are 
measures (MMWR/CDC, 1998) are implied:  
1.  Early diagnosis and effective treatment of TB among HIV-infected patients are critical for 
curing TB, minimizing the negative effects of TB on the course of HIV, and interrupting the 
transmission of Mycobacterium tuberculosis to other persons in the community.  
 47 
 
2. All HIV-infected persons at risk for infection with M. tuberculosis must be carefully 
evaluated and, if indicated, administered therapy to prevent the progression of latent 
infection to active TB disease and avoid the complications associated with HIV-related TB.  
3. All HIV-infected patients undergoing treatment for TB should be evaluated for 
antiretroviral therapy, because most patients with HIV-related TB are candidates for 
concurrent administration of antituberculosis and antiretroviral drug therapies. However, the 
use of rifampin with protease inhibitors or non-nucleoside reverse transcriptase inhibitors is 
contraindicated.  
4. Missed opportunities for HIV treatment at the time of TB treatment is a common 
phenomenon underscoring the need for integration of TB and HIV diagnostic services 
(Tribble, 2009). 
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Chapter 5: Strengths and Limitations 
 
5.1 The strengths of this study  
 
These include: 
1. The data are not hospital based. 
2. A study population was recruited from the general population and so it was a 
generally healthy population, thus giving a picture of what is the situation of the need 
among the HIV infected in the general population. 
5.2 Limitations of the study 
 
1. The study population comprised of women solely who are HIV-1 seropositive and 
HSV-2 co-infected; thus may not be generalizable to other HIV only infected women 
in the general population, men or children.  
2. Rarity of some important symptoms and signs as the study population was still 
asymptomatic.  
3. Measurement (information) bias. The low index of suspicion of some clinical features 
e.g. oral hairy leukoplakia (Schiødt, 1990) which are normally not frequently 
detected by clinicians during physical examination. This could lead to underestimate 
the number of symptoms/signs that predict CD4 + count < 200 cells/µL. 
4. Very few patients were in WHO clinical stages III/IV. The small numbers in this 
category could make some associations to be due to chance and lead to a lack of 
accuracy in sensitivity calculations. 
 49 
 
5. Biases of the recruitment and the exclusion: Patients in WHO stages I/II only had 
their CD 4 + count measured at the screening phase of the clinical trial. Patients with 
WHO clinical stages III/IV were immediately referred for treatment. This led to a 
majority of the study population analysed being in WHO stages I/II. 
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Chapter 6: Conclusions and Recommendations 
 
In summary, these results show that the WHO clinical staging is inadequate as a tool to  
predict the need for initiating ART in a population of women who are still asymptomatic. If 
clinical staging is used alone as many as 13% of women would have gone untreated. 
Initiation of HAART would have been deferred in these patients until they reached a more 
advanced HIV clinical stage when treatment outcomes are likely to be less successful 
(Wilkin, 2008). This study shows that certain signs are strongly associated with the need to 
initiate treatment. These conditions are relatively infrequent in the general population, but 
when observed should alert clinicians to the need for treatment in these patients. Of interest 
was the finding that a history of TB is strongly associated with a CD4 < 350 cells/µL and 
that this may be a useful indicator for initiating HIV treatment in a South African population. 
Given the fact that the HIV incidence is still rising it can be expected that the health care 
facilities will be over burdened in the near future by HIV and the associated opportunistic 
infections in the near future. (Dorrington, 2004, Kober K and Van Damme W, 2004). From 
this study, we therefore suggest encouraging more HIV positive people to come forward for 
treatment through intensifying campaigns for VCT for early diagnosis and treatment. Those 
eligible will be identified and brought to treatment as early as possible.  
Given the findings of this study it is recommended that CD4 + count testing should be the 
most reliable indicator of when to start treatment. Where testing is restricted: 
1. CD 4 + count measurements could be targeted at those without obvious predictors of 
immunocompromise. 
2. The overall diagnostic accuracy (i.e. the ability to detect correctly all those who 
require and do not require HAART) of WHO staging criteria could increase using the 
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combination of other parameters like BMI, haemoglobin, TLC and an active WHO 
indicator disease (Zachariah R, 2005; Erhabor, 2006). Simple, inexpensive laboratory 
determination of haemoglobin, and a non laboratory procedure like BMI 
determination should be combined with the symptom/signs identified to initiate 
HAART. The thresholds of such parameters with these identified symptoms and 
signs predicting CD4 + counts < 350 cells/µL are a subject of the next investigation 
although not looked at in this study. 
 
We thus conclude by having shown symptoms and signs which best predict the need for 
HAART initiation in the absence of CD4  + measurement to be generalized skin rash, 
dehydration and oral thrush (candida).We recommend that clinical assessment alone should 
not replace CD4 + testing in identifying asymptomatic people in the general population that 
need treatment by HAART. This calls for more campaign for VCT and more resource 
allocation in HIV care and treatment. 
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8.0 Appendices 
 
Appendix E.1 QUESTIONNAIRE USED FOR THE MAIN TRIAL: THE EFFECT OF 
ANTI-HERPETIC SUPPRESSIVE THERAPY ON HIV SHEDDING IN SOUTH 
AFRICAN WOMEN WHO ARE SEROPOSITIVE FOR HIV AND HSV2: A 
RANDOMISED CONTROLLED TRIAL 
                    [visitCode]  Visit code ## 
                   We want to learn about aspects of your health related to your HIV infection. 
1.  [firsthiv] Date of first known positive test 
for HIV? (dd/mmm/yy) 
[inhivdate] – Incomplete date e.g (01-
JAN-YYYY) 
//
 
2. 
 
In the past 12 months, have you had any of the following health 
problems?  
If “Yes” to shaded items, then participant is ineligible (WHO Stage 3-4). 
  
Yes No 
D
o
n
’
t 
k
n
o
w 
2a [sore] Persistent genital OR oral 
sores > 1 month? 
1 
 
2 
 
98 
 
2b [wtloss] Substantial unintentional 
weight loss (>= 10% body weight)? 
1 
 
2 
 
98 
 
2c [diamth] Diarrhea > 1 month (>= 3 
loose stools/day)?    
1 
 
2 
 
98 
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2d [diawk] Diarrhea > 1 week but < 1 
month?  
1 
 
2 
 
98 
 
2e [pain] Pain or difficulty with 
swallowing? 
1 
 
2 
 
98 
 
2f [fevmth] Fever > 1 month? 1 
 
2 
 
98 
 
2g [fevwk] Fever > 1 week but < 1 
month? 
1 
 
2 
 
98 
 
2h [coughmth] Cough > 1 month? 1 
 
2 
 
98 
 
2i [coughwk] Cough > 1 week but < 1 
month? 
1 
 
2 
 
98 
 
2j [sweatmth] Night sweats > 1 
month 
1 
 
2 
 
98 
 
2k [sweatwk] Night sweats > 1 week 
but < 1 month 
1 
 
2 
 
98 
 
2l [Headmth] Headache > 1 month? 1 
 
2 
 
98 
 
2m [Headwk] Headache > 1 week but 
< 1 month? 
1 
 
2 
 
98 
 
2n [Bed] Confined to bed for more 
than half the daytime 
1 
 
2 
 
98 
 
2o [Rash] Generalized body rash? 1 
 
2 
 
98 
 
2p [Glands] Swollen glands in the 
neck or armpits? 
1 
 
2 
 
98 
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3. In the past 12 months, have you been diagnosed by a health care provider 
with…? 
If “Yes” to shaded items, then participant is ineligible 
  
Yes No 
Don’t 
know 
3a [seizure] Seizures  1 
 
2 
 
98 
 
3b [renal]  Renal failure 1 
 
2 
 
98 
 
3c [pneumo] Pneumonia 1 
 
2 
 
98 
 
3d [meningitis]  Meningitis 1 
 
2 
 
98 
 
3e [tb] Tuberculosis (TB) 1 
 
2 
 
98 
 
3f [candida] Oral thrush (Candida) 1 
 
2 
 
98 
 
3g [shingles] Zoster (shingles) 1 
 
2 
 
98 
 
3h [kaposis] Kaposi’s sarcoma 1 
 
2 
 
98 
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3i [otheropp] Other opportunistic 
infections 
[speopp] Specify: 
1 
 
2 
 
98 
 
 
4 [hosp] In the past 12 months, have you 
been hospitalized for any condition? 
Yes=1 
No=2  
Don’t know=98  
 
 
  Go to SPE 
4a [nohosp] If YES, how many times have 
you been hospitalized in the past 12 
months? 

4b What was the reason for admission? 
 
 
[admit1] 1.__ TEXT 
_________________ 
 
[admit2] 2.__ TEXT 
_________________ 
 
[admit3] 3.__TEXT 
__________________ 
 
 
SCREENING I:  PHYSICAL EXAMINATION (SPE) PAGEE 74 OF 
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[ptid] Participant ID   - (S-####-#)  Visit date // 
(dd/mmm/yy) 
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1. 1. [ptwt] Patient weight . kg 
   
2. General examination Yes No 
Not 
examined 
a [tired] Participant looks tired 1 2 88 
b [temp] Elevated temperature 1 2 88 
c [pallor] Pallor 1 2 88 
d [jaundice] Jaundice 1 2 88 
e [dehyd] Dehydration 1 2 88 
f [lymph] Lymphadenopathy (in ≥ 2 
extragenital sites) 
1 2 88 
g [edema] Oedema 1 2 88 
 
3. Skin  Yes No 
Not 
examined 
a [skinrash] Generalised skin rash 1 2 88 
b [skinzos] Zoster 1 2 88 
c [skinkap] Kaposi’s sarcoma  If YES, 
ineligible 
1 2 88 
d [othskin] Other, 
[speskin] specify: TEXT 
1 2 88 
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[ptid] Participant ID   - (S-####-#)  Visit date // 
(dd/mmm/yy) 
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4. Oral exam   Yes No 
Not 
examined 
a [oralthrush] Thrush  If YES, ineligible 1 2 88 
b [ohl] OHL (oral hairy leukoplakia)  If YES, 
ineligible 
1 2 88 
c [oralkap] Kaposi’s sarcoma  If YES, ineligible 1 2 88 
d [oralulcer] Ulcers 1 2 88 
e [ginperid] Gingivitis/periodontitis 1 2 88 
f [othoral] Other 
[speoral] specify: TEXT 
 
1 2 88 
 
5. Chest Yes No 
Not 
examined 
a [tachyp] Tachypnoea  1 2 88 
b [cynosis] Cyanosis 1 2 88 
c [pleural] Pleural effusion 1 2 88 
d [bronchial] Signs of bronchial or parenchymal 
disease 
1 2 88 
e [othchest] Other 
[spechest]  specify: TEXT 
1 2 88 
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(dd/mmm/yy) 
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6. Abdomen Yes No 
Not 
examined 
a [hepato] Hepatomegaly 1 2 88 
b [spleno] Splenomegaly 1 2 88 
c [ascites] Ascites 1 2 88 
d [abdm] Abdominal mass 1 2 88 
 
7. Nervous system Yes No 
Not 
examined 
a [meng] Meningism 1 2 88 
b [abngait] Abnormal gait 1 2 88 
c [periph] Peripheral neuropathy 1 2 88 
d [Palsy] Visible palsy/paresis 1 2 88 
e [visd] Visual disturbances 1 2 88 
f [cogd] Cognitive deficit 1 2 88 
 
Comments:  
____________________________________________________________________________________
_______________________ 
 
 
SCREENING I:  PHYSICAL EXAMINATION (SPE) PAGEE 77 OF 
100 
[ptid] Participant ID   - (S-####-#)  Visit date // 
(dd/mmm/yy) 
77 
 
 
 
 
 
FINAL ASSESSMENT OF HIV DISEASE STATUS 
8 [wstage] Indicate stage of HIV disease based on 
WHO Clinical Staging System 
Stage 1/2 = 
1 
 Collect CD4+ 
Stage 3/4 = 
2 
 
 
 Ineligible 
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                                   Instructions for WHO Clinical Staging of HIV 
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Inclusion Criteria 
Items 1–6 must be answered “yes” for participant to be eligible. 
  Yes No 
1 [legage] Is the participant of legal age to provide independent 
informed consent i.e. 18 years or older? 
 
1 2 
2 
 
[conct] Was the participant willing and able to provide 
independent written informed consent for screening?  
 
2a. [sgcon] When was the informed consent for screening signed or 
marked?   / /
1 2 
3 [locator] Was the participant willing and able to provide adequate 
locator information? 
 
1 2 
4 [adh] Is the participant willing and able to undergo clinical 
examinations, take study drug as directed for the specified period 
and adhere to the visit schedule? 
 
1 2 
5 [contra] Is the participant using a reliable method of 
contraception?  
 
5a.  [spcontra] Specify method of family planning here: TEXT 
1 2 
 Items 6 is read aloud to the participant.  Yes No 
6 [address] Have you been staying at your current address for > one 
month? 
1 2 
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Items 6–17 must be answered “no” for participant to be eligible 
 
  Yes No 
7 [stage34] Does the participant have evidence of WHO Stage 3-4 disease? 1 2 
8 [coind] Does the participant have any contra-indications to the use of 
acyclovir (epilepsy, kidney failure)? 
1 2 
 Items 8–17 are read aloud to the participant.  Yes No 
9 [trial] Are you currently enrolled in any other HIV treatment or 
prevention trial? 
1 2 
10 [arv] Are you currently taking any anti-HIV medicines (anti-retrovirals) 1 2 
11 [adv] Have you ever had a known “bad” (adverse) reaction to acyclovir? 1 2 
12 [hepmed] Are you currently taking any medicines such as acyclovir, 
valacyclovir, famciclovir, or foscarnet for the daily treatment of genital 
herpes? 
1 2 
13 [gud] Have you had a genital ulcer for more than one month which does 
not get better with treatment? 
1 2 
14 [epigen] Have you experienced > 6 episodes of genital herpes in the past 
year (twelve months)? 
1 2 
15 [cpreg] Are you currently pregnant or do you suspect that you might be 
pregnant? 
 
1 2 
17 [tpreg] Are you planning to become pregnant in the next four months? 1 2 
18 [travel] Do you plan to travel out of the study area for more than two 
weeks in a row while enrolled in the trial? 
1 2 
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Note that Final Eligibility is determined once Screening Laboratory Results Form (SLR) is completed. 
 
 
1 
[hivd] HIV specimen collection date    // (dd/mmm/yy) 
[inhiv] HIV specimen collection date 0=Not apply 1. Apply    If no proof of test 
results available, perform rapid test to confirm status 
 
2 
[hivst] 
HIV 
status              
 
Positive = 1     
Negative = 2 
 
Ineligible 
 
3 
[hsvd] HSV-2 specimen collection date  // (dd/mmm/yy) 
[inhsv] Incompleted HSV-2 specimen collection date 0=Not apply 1. Apply  
4 
[hsvind
] HSV-
2 index 
.If >3.4 go to item 6 
 
If  1.1-3.4 go to item 5 
 
If <1.1 ineligible 
 
5 [kalon 
] Kalon 
HSV-2 
EIA 
Resolve 
equivoc
al 
results 
Positive = 1  
Negative = 2  
Not done = 9  
Go to item 6 
Ineligible 
SCREENING I:  PHYSICAL EXAMINATION (SPE) PAGEE 83 OF 100 
[ptid] Participant ID   - (S-####-#)  Visit date // 
(dd/mmm/yy) 
83 
 
(Index 
1.1-3.4) 
 
6 [urined] Urine specimen collection date  // (dd/mmm/yy) 
7 
[pregt] 
Pregnan
cy test 
result 
Positive = 1  
Negative = 2  
Ineligible 
 
 
8 
[scrlysis
] 
Urinalys
is 
Protein 3+ = 1 
<Protein 3+ = 2  
Ineligible 
 
 
9 
[cd4d] CD4+ specimen collection date  // (dd/mmm/yy) 
[incd4] Incomplete CD4
+   
specimen collection date. 0=Not apply 1. Apply 
10 
[cd4c] 
CD4 
count 
/μl 
 
 If < 250, ineligible 
11 
[cd4p] 
CD4 
Percent 
. % 
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Appendix E.2 ETHICAL CLEARANCE FROM ETHICS COMMITTEE. 
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